Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 245 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Needle-Syringe Clear all

Conditions: Pain
Interventions: 30-gauge needle, 32-gauge needle; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 25 Years to 70 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anesthesia
Interventions: Dental local anesthesia; Procedure
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 4 Years to 10 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetic Retinopathy
Interventions: Ketorolac 0.45% ophthalmic solution, Placebo - Preservative-free artificial tears, Aqueous PGE2 and inflammatory cytokines measurements; Drug · Other
Lead sponsor: Stephen J. Kim, MD; Other
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Opioid Dependence
Interventions: Smartphone Application; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Frown Lines
Interventions: Botulinum toxin A "BoNT/A-DP", Botulinum toxin A "Botox Cosmetics"; Biological
Lead sponsor: Croma-Pharma GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Santa Monica, California • Coral Gables, Florida

Conditions: Pain, Anxiety
Interventions: Virtual Reality, Standard Procedure Thyroid Biopsy, Standard Procedure PICC Placement; Device · Procedure
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pain Assessment, Quality of Life (QOL), Analgesic Use
Interventions: Supplemental Postoperative Bupivacaine, Placebo Injection; Drug
Lead sponsor: New York University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Pain
Interventions: 12 mL paracervical block, 20 mL paracervical block; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Branch Retinal Vein Occlusion
Interventions: Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 26
States / cities: Phoenix, Arizona • Mountain View, California • Santa Barbara, California + 21 more

Conditions: Healthy Adults
Interventions: LectraJet, TIV by jet injection, Seasonal Trivalent Influenza Vaccine; Device · Biological
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 49 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: College Park, Maryland

Conditions: Ricin Poisoning
Interventions: RVEc; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Fort Deterick, Maryland

Conditions: IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease
Interventions: Atacicept 150 mg; Drug
Lead sponsor: Vera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Lateral Epicondylitis (Tennis Elbow)
Interventions: Platelet Rich Plasma (PRP) Injection, Whole Blood Injection, Dry Needle Fenestration, Sham Injection; Other
Lead sponsor: McMaster University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Wet Age-related Macular Degeneration
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 50 Years and older
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 65
States / cities: Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 60 more

Conditions: Knee Osteoarthritis
Interventions: Ketorolac, Betamethasone; Drug
Lead sponsor: St. Luke's Hospital, Pennsylvania; Other
Eligibility: 18 Years and older · Male only
Enrollment: 448 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bethlehem, Pennsylvania

Conditions: Diabetic Foot, Venous Ulcer, Pressure Ulcer
Interventions: Adipose derived stem cells; Drug
Lead sponsor: Tower Outpatient Surgical Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Age-Related Macular Degeneration
Interventions: E10030, bevacizumab or aflibercept, E10030 sham injection; Drug
Lead sponsor: Ophthotech Corporation; Industry
Eligibility: 50 Years and older
Enrollment: 645 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 100
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 88 more

Conditions: Marburg Virus Disease
Interventions: cAd3-Marburg Vaccine, Placebo; Biological
Lead sponsor: Albert B. Sabin Vaccine Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 7
States / cities: Huntsville, Alabama • Phoenix, Arizona • Melbourne, Florida + 4 more

Conditions: HIV/AIDS
Interventions: Enhanced Intervention, Basic Intervention; Behavioral
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Uveitis, JIA
Interventions: Adalimumab, Placebo; Biological · Other
Lead sponsor: Nisha Acharya; Other
Eligibility: 2 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 11
States / cities: Sacramento, California • San Francisco, California • Aurora, Colorado + 8 more

Conditions: Shoulder Arthroscopy
Interventions: Bupivacaine with Epinephrine, Bupivacaine alone; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: DNA Nat-B env, DNA CON-S env, DNA Mosaic env, MVA-CMDR, Placebo for DNA Nat-B env, Placebo for DNA CON-S env, Placebo for DNA Mosaic env, Placebo for MVA-CMDR; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 6
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 2 more

Conditions: Rhegmatogenous Retinal Detachment - Macula Off
Interventions: ONL1204 Ophthalmic Solution, Sham treatment; Drug
Lead sponsor: ONL Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 36
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 32 more

Conditions: Raynaud Phenomenon
Interventions: Botulinum toxin; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

A Pilot Study of Needle Size and Pain Perception With Botulinum Toxin A Injections

Comparison of Articaine Mandibular Infiltration to Lidocaine Inferior Alveolar Nerve Block in Pediatric Patients

INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study

Needle-X: Usability Testing of a Smartphone Application

Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines

Virtual Reality for the Management of Pain and Anxiety for Outpatient Interventional Radiology Procedures

Supplemental Postoperative Bupivacaine Following Non-Surgical Endodontic Treatment

12 Versus 20 mL PCB for D&E Cervical Prep

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

Safety Study of Seasonal Influenza Vaccine by Jet Injection

IM Recombinant Ricin Toxin Vaccine (RVEc) - 3-Dose Primary Series With Boost

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

Comparison of Platelet Rich Plasma and Alternative Therapies for the Treatment of Tennis Elbow (Lateral Epicondylitis)

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)

Comparing Intra-articular Corticosteroid to Intra-articular Ketorolac Knee Injections

Adipose Derived Regenerative Cellular Therapy of Chronic Wounds

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults

PrEP Communication Intervention for Female Clients of a Needle Exchange

Adalimumab in JIA-associated Uveitis Stopping Trial

Subacromial Injection of Epinephrine Improves Visualization in Shoulder Arthroscopy

Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults

A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment

Botulinum Toxin in Raynaud's Phenomenon